Virometix

This early-stage trial is testing a new vaccine called V-212, designed to protect against pneumococcal disease caused by the bacterium Streptococcus pneumoniae. The study involves 60 healthy adults aged 18-45 who will receive either the vaccine or a placebo in three doses. Resear…